Bruno Laugel
University of Oxford
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Bruno Laugel.
Nature Medicine | 2008
Angel Varela-Rohena; Peter Eamon Molloy; Steven M. Dunn; Yi Li; Richard G. Carroll; Anita Milicic; Tara Mahon; Deborah H. Sutton; Bruno Laugel; Ruth Moysey; Brian J. Cameron; Annelise Vuidepot; Marco E. Purbhoo; David K. Cole; Rodney E. Phillips; Carl H. June; Bent K. Jakobsen; Andrew K. Sewell; James L. Riley
HIVs considerable capacity to vary its HLA-I-restricted peptide antigens allows it to escape from host cytotoxic T lymphocytes (CTLs). Nevertheless, therapeutics able to target HLA-I-associated antigens, with specificity for the spectrum of preferred CTL escape mutants, could prove effective. Here we use phage display to isolate and enhance a T-cell antigen receptor (TCR) originating from a CTL line derived from an infected person and specific for the immunodominant HLA-A*02-restricted, HIVgag-specific peptide SLYNTVATL (SL9). High-affinity (KD < 400 pM) TCRs were produced that bound with a half-life in excess of 2.5 h, retained specificity, targeted HIV-infected cells and recognized all common escape variants of this epitope. CD8 T cells transduced with this supraphysiologic TCR produced a greater range of soluble factors and more interleukin-2 than those transduced with natural SL9-specific TCR, and they effectively controlled wild-type and mutant strains of HIV at effector-to-target ratios that could be achieved by T-cell therapy.
elly Tie Knit Dress Ribbed dee Strap 75d7q & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
amp; Alexis Gray Flare Fit Dress Alton Z4AwqHZ & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Z Zella Waist Leggings High By Daily r5F14cWgr & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Yoga Pant James Riding Perse Perse James xrrwWqXtS & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Workshop Terry Dress Hooded French Short Sleeve q8xaAqZ7n & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Velvet One Parker Shoulder Rima Blouse qatfAwx7z & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Vanity Room Midi Neck Dress Knit Mock Popover H7w8a & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Vanity Maxi Waist Smocked Room Dress Uz4WzX1 & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Turtleneck Chelsea28 Layering Layering Chelsea28 Chelsea28 Turtleneck HqP4wO7 & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.